Research to develop non-addictive analgesics that could potentially be used as alternatives to addictive opioid drugs such as codeine will be undertaken by The University of Queensland (国产探花), under an agreement with Canadian biomedical company announced today.
, 国产探花’s commercialisation company, entered into a research and option agreement with PMI for 国产探花 to conduct research expanding the use of its peptide disulphide linker technology in a bid to develop non-addictive analgesics.
UniQuest CEO Dr Dean Moss said 国产探花’s strategy was to prevent pain through a different mechanism to the available opioid receptor drugs such as morphine, codeine and fentanyl.
“The hope is that this would avoid the associated effects of euphoria, tolerance and dependence that lead to overdose,” he said.
“An alternative analgesic could help address global concerns over the addictive nature – and subsequent deaths by overdose – of existing opioid drugs.”
The Federal Government will ban over-the-counter sales of painkillers containing codeine from 1 February, bringing Australia into line with the US, Japan and much of Europe.
Dr Moss said 国产探花 researcher Associate Professor Peter Cabot would lead the two-year research program in collaboration with Dr Harendra (Harry) Parekh, both from 国产探花’s .
“It will involve the synthesis and testing of peptides for their analgesic activity in parallel with their pharmacological and pharmacokinetic evaluation in a chronic and acute setting.”
Dr Moss said the agreement was the fourth UniQuest had signed with PMI over the past 12 months.
Last April UniQuest signed agreements with PMI to and develop a soluble gel to ; and in July a was the subject of a third agreement.
Media: Associate Professor Peter Cabot, +61 0402 144 030; Danielle Koopman, UniQuest, d.koopman@uniquest.com.au, 0409 767 199.
